---
title: "Chengdu Olymvax Biopharmaceuticals Inc (688319.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688319.SH.md"
symbol: "688319.SH"
name: "Chengdu Olymvax Biopharmaceuticals Inc"
industry: "Biotechnology"
datetime: "2026-05-21T16:14:08.911Z"
locales:
  - [en](https://longbridge.com/en/quote/688319.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688319.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688319.SH.md)
---

# Chengdu Olymvax Biopharmaceuticals Inc (688319.SH)

## Company Overview

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.olymvax.com](https://www.olymvax.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 9 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 27.90% |  |
| Net Profit YoY | 42.45% |  |
| P/B Ratio | 17.07 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 15861067573.27 |  |
| Revenue | 772985003.76 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.11% | C |
| Profit Margin | 7.30% | B |
| Gross Margin | 91.84% | A |
| Revenue YoY | 27.90% | A |
| Net Profit YoY | 42.45% | B |
| Total Assets YoY | 13.86% | B |
| Net Assets YoY | 0.30% | C |
| Cash Flow Margin | 183.24% | B |
| OCF YoY | 27.90% | A |
| Turnover | 0.41 | C |
| Gearing Ratio | 53.90% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Chengdu Olymvax Biopharmaceuticals Inc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "27.90%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "42.45%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "17.07",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "15861067573.27",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "772985003.76",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.11%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.30%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "91.84%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "27.90%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "42.45%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.86%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.30%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "183.24%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "27.90%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "53.90%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 256.39 | 41/81 | 221.65 | 176.86 | 159.94 |
| PB | 15.57 | 73/81 | 12.88 | 11.01 | 9.51 |
| PS (TTM) | 18.71 | 67/81 | 16.75 | 15.13 | 13.36 |
| Dividend Yield | 0.00% | - | 0.24% | 0.22% | 0.21% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-17T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 35.72 |
| Highest Target | 28.00 |
| Lowest Target | 28.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688319.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688319.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688319.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**